| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701760 | Journal of Thoracic Oncology | 2016 | 10 Pages |
Abstract
The PRAME immunotherapeutic had an acceptable safety profile. All patients had anti-PRAME humoral responses that were not dose related, and 80% of those treated at the highest dose showed a cellular immune response. The dose of 500 μg was selected. However, further development was stopped after negative results with a similar immunotherapeutic in patients with NSCLC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jean-Louis MD, Tommaso MD, Achim MD, PhD, Eric MD, Bartosz MD, PhD, Eugeny MD, Sebastian MD, Gregory A. MD, Robert MD, Sergei A. MD, PhD, Hans-Stefan MD, Nicolas PhD, Bruno PhD, Muriel SSc, Silvija MD, PhD, Pedro Miguel PhD, Jamila PhD, Vincent G. MD,